GenfitFRA:XUPB +10.81%68 Days Payable is 19,078.91 as of Dec. 2025, which is 30% below its 10-year median of 27,246.67. GuruFocus rates FRA:XUPB with a GF Score™ of 68/100 and a GF Value™ of €4.16. The stock has 10 warning signs investors should review. Among 702 Biotechnology companies, Genfit ranks better than 96.58% on this metric.
Genfit's average Accounts Payable for the
six
months ended in Dec. 2025 was €14.95 Mil. Genfit's Cost of Goods Sold for the
six
months ended in Dec. 2025 was €0.14 Mil.
Hence, Genfit's Days Payable for the
six
months ended in Dec. 2025 was 19,078.91.
The historical rank and industry rank for Genfit's Days Payable or its related term are showing as below:
FRA:XUPB'
s Days Payable Range Over the Past 10 Years
Min: 1711.55 Med: 27246.67 Max: 74885.83
Current: 17458.76
During the past 13 years, Genfit's highest Days Payable was 74885.83. The lowest was 1711.55. And the median was 27246.67.
FRA:XUPB's Days Payable is ranked better than 96.58% of 702
companies
in the Biotechnology industry
Industry Median: 113.56
vs FRA:XUPB: 17458.76
Genfit's Days Payable
increased
from Dec. 2024 (13,422.50) to Dec. 2025 (19,078.91).
It may suggest that Genfitdelayed paying its suppliers.
Genfit Days Payable Related Terms
Genfit Days Payable Historical Data
* Premium members only.
The historical data trend for Genfit's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:XUPB vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Genfit's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genfit Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genfit's Days Payable distribution charts can be found below:
* The bar in red indicates where Genfit's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Genfit's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genfit (FRA:XUPB) has a Days Payable of 19,078.91 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Genfit and its competitors. This is 30% below median its historical median of 27,246.67. Over the past decade, Genfit's Days Payable has ranged from 1,711.55 to 74,885.83. According to the industry distribution chart, Genfit ranks #24 out of 702 companies in the Biotechnology industry, placing it in the top 3.4%.
Is Genfit's Days Payable too high?
Genfit's current Days Payable of 19,078.91 is 30% below median its 10-year median of 27,246.67. Over the past 10 years, this metric has ranged from a low of 1,711.55 to a high of 74,885.83. The Biotechnology industry median Days Payable is 113.56. Genfit's value of 19,078.91 is 16700.7% above this industry median. Based on the distribution chart, Genfit ranks #24 out of 702 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Genfit has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Genfit's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genfit ranks #24 out of 702 companies for Days Payable. This places Genfit in the top 3% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.56. Genfit's value of 19,078.91 is 16700.7% above this benchmark. Historically, Genfit's own Days Payable has ranged from 1,711.55 to 74,885.83 over the past decade. While the company's 10-year median is 27,246.67 vs. the industry median of 113.56, Genfit has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genfit's current Days Payable of 19,078.91 is 16700.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Genfit and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genfit's current Days Payable is 19,078.91, which is 30% below median its own 10-year median of 27,246.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genfit stock overvalued right now?
Genfit (FRA:XUPB) has a current Days Payable of 19,078.91. The stock's GF Value™ is €4.16, compared to a current price of €6.15 — trading 47.8% above its estimated fair value. The current Days Payable is 19,078.91, which is 30% below median its 10-year median of 27,246.67 and 16700.7% above the Biotechnology industry median of 113.56. Genfit's overall GF Score™ is 68/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Genfit (FRA:XUPB), the current Days Payable is 19,078.91 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genfit (FRA:XUPB) Overvalued in 2026?
Based on GuruFocus' analysis, Genfit stock appears to be overvalued.
The current stock price of €6.15 is trading 47.8% above its estimated GF Value™ of €4.16.
Key valuation signals for FRA:XUPB:
Days Payable: 19,078.91 (30% below median its 10-year median of 27,246.67)
GF Value™: €4.16 vs. price of €6.15 (47.8% above fair value)
Industry Position: 16700.7% above the Biotechnology median (#24 of 702)
No single metric tells the full story. See the FRA:XUPB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements to fund the further development of its products. It has one segment, the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
68GF Score
Get the complete analysis for FRA:XUPB
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:XUPB has been successfully added to your 
